[Intrahepatic cholestasis of pregnancy: French College of Obstetricians and Gynecologists guidelines for clinical practice]
- PMID: 37806861
- DOI: 10.1016/j.gofs.2023.09.004
[Intrahepatic cholestasis of pregnancy: French College of Obstetricians and Gynecologists guidelines for clinical practice]
Abstract
Objective: To identify strategies for reducing neonatal and maternal morbidity associated with intrahepatic cholestasis pregnancy (ICP).
Material and methods: The quality of evidence of the literature was assessed following the GRADE methodology with questions formulated in the PICO format (Patients, Intervention, Comparison, Outcome) and outcomes defined a priori and classified according to their importance. An extensive bibliographic search was performed on PubMed, Cochrane, EMBASE and Google Scholar databases. The quality of the evidence was assessed (high, moderate, low, very low) and a (i) strong or (ii) weak recommendations or (iii) no recommendation were formulated. The recommendations were reviewed in two rounds with external reviewers (Delphi survey) to select the consensus recommendations.
Results: Of the 14 questions (from 12 PICO questions and one definition question outside the PICO format), there was agreement between the working group and the external reviewers on 14 (100%). The level of evidence of the literature was insufficient to provide a recommendation on two questions. ICP is defined by the occurrence of suggestive pruritus (palmoplantar, nocturnal) associated with a total bile acid level>10μmol/L or an alanine transaminase level above 2N after ruling out differential diagnoses. In the absence of suggestive symptoms of a differential diagnosis, it is recommended not to carry out additional biological or ultrasound tests. In women with CIP, ursodeoxycholic acid is recommended to reduce the intensity of maternal pruritus (Strong recommendation. Quality of the evidence moderate) and to decrease the level of total bile acids and alanine transaminases. (Strong recommendation. Quality of the evidence moderate). S-adenosyl-methionine, dexamethasone, guar gum or activated charcoal should not be used to reduce the intensity of maternal pruritus (Strong recommendation. Quality of evidence low), and there is insufficient data to recommend the use of antihistamines (No recommendation. Quality of evidence low). Rifampicin (Weak recommendation. Very low quality of evidence) or plasma exchange (Strong recommendation. Very low quality of evidence) should not be used to reduce maternal pruritus and perinatal morbidity. Serum monitoring of bile acids is recommended to reduce perinatal morbidity and mortality (stillbirth, prematurity) (Low recommendation. Quality of the evidence low). The level of evidence is insufficient to determine whether fetal heart rate or fetal ultrasound monitoring are useful to reduce perinatal morbidity (No recommendation). Birth is recommended when bile acid level is above 99μmol/L from 36 weeks gestation to reduce perinatal morbidity, in particular stillbirth. When bile acid level is above 99μmol/L is below 100μmol/L, women should be informed that induction of labor could be considered 37 and 39 weeks gestation to reduce perinatal morbidity. (Strong recommendation. Quality of evidence low). In postpartum, total bile acids and alanine transaminases level should be checked and normalized before prescribing estrogen-progestin contraception, ideally with a low estrogen dose (risk of recurrence of pruritus and cytolysis) (Low recommendation. Quality of evidence very low).
Conclusion: Although the quality of evidence regarding ICP gestational cholestasis remains low, there is a strong consensus in France, as shown by our Delphi study, on how to manage women with ICP. The reference first-line treatment is ursodeoxycholic acid.
Keywords: Acides biliaires; Bile acids; Cholestase gravidique; Contraception; Déclenchement; Fetal death in utero; Induction of labor; Intrahepatic cholestasis pregnancy; Maternal morbidity; Monitoring; Morbidité maternelle; Morbidité périnatale; Mort fœtale in utero; Neonatal morbidity; Prematurity; Prurit; Pruritus; Prématurité; Stillbirth; Surveillance; Transaminases.
Copyright © 2023 CNGOF. Published by Elsevier Masson SAS.. All rights reserved.
Similar articles
-
[Preeclampsia: Guidelines for clinical practice from the French College of Obstetricians and Gynecologists].Gynecol Obstet Fertil Senol. 2024 Jan;52(1):3-44. doi: 10.1016/j.gofs.2023.10.002. Epub 2023 Oct 25. Gynecol Obstet Fertil Senol. 2024. PMID: 37891152 French.
-
[The cesarean procedure: Guidelines for clinical practice from the French College of Obstetricians and Gynecologists].Gynecol Obstet Fertil Senol. 2023 Jan;51(1):7-34. doi: 10.1016/j.gofs.2022.10.002. Epub 2022 Oct 11. Gynecol Obstet Fertil Senol. 2023. PMID: 36228999 French.
-
Pharmacological interventions for treating intrahepatic cholestasis of pregnancy.Cochrane Database Syst Rev. 2020 Jul 27;7(7):CD000493. doi: 10.1002/14651858.CD000493.pub3. Cochrane Database Syst Rev. 2020. PMID: 32716060 Free PMC article.
-
Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: Replaces Consult #13, April 2011.Am J Obstet Gynecol. 2021 Feb;224(2):B2-B9. doi: 10.1016/j.ajog.2020.11.002. Epub 2020 Nov 13. Am J Obstet Gynecol. 2021. PMID: 33197417 Review.
-
Intrahepatic cholestasis of pregnancy: a comparison of Society for Maternal-Fetal Medicine and the Royal College of Obstetricians and Gynaecologists' guidelines.Am J Obstet Gynecol MFM. 2023 Mar;5(3):100838. doi: 10.1016/j.ajogmf.2022.100838. Epub 2022 Dec 9. Am J Obstet Gynecol MFM. 2023. PMID: 36503152 Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical